Cite
HARVARD Citation
Schubert, M. et al. (2019). Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol. BMJ open. 9 (5), p. . [Online].